title: Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with syringopicroside.
abstract: A solvent emulsification evaporation method was employed to prepare solid lipid nanoparticles (SLN) loaded with syringopicroside. The conventional broad-spectrum antibacterial and antiviral drug syringopicroside was incorporated into SLN to improve drug targeting. The SYR-SLNs were spherical and uniform in transmission electron microscopy (TEM). The mean particle size and potential were 180.31 +/- 10 nm, and -41.9 +/- 10.3 mV, respectively. Also, a sephadex column chromatography was adopted to investigate the encapsulation efficiency (EE %) of the SLN. This method is based on the principle of molecular sieve effect, and the EE% of the optimal formulation was 42.35 %. Drug-loading capacity was 5.33 %. The in vitro release profile revealed that syringopicroside was released from SLN efficiently and completely in normal saline (NS) compared with other release media. A HPLC method was established for in vivo assay of syringopicroside. A tissue distribution study was conducted in rats after iv administration of 15 mg/kg SYR-SLN and syringopicroside NS, and it was found that SYR-SLN has improved delivery to the liver compared with any other organizations. These results indicated that solvent emulsification evaporation is a simple, easy, available and effective method for preparing SYR-SLN.
authors.affiliation: College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, P. R. China.
authors.forename: Xiwu
authors.initials: X
authors.lastname: Zhang
authors.forename: Shaowa
authors.initials: S
authors.lastname: Lü
authors.forename: Jihong
authors.initials: J
authors.lastname: Han
authors.forename: Shuang
authors.initials: S
authors.lastname: Sun
authors.forename: Limin
authors.initials: L
authors.lastname: Wang
authors.forename: Yongji
authors.initials: Y
authors.lastname: Li
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000737:chemistry* / Q000493:pharmacokinetics; D019540:Area Under Curve; D002626:Chemistry, Pharmaceutical; D004563:Electrochemistry; D004655:Emulsions; D005079:Excipients; D005990:Glycerol / Q000031:analogs & derivatives / Q000737:chemistry; D006027:Glycosides / Q000008:administration & dosage* / Q000737:chemistry* / Q000493:pharmacokinetics; D007275:Injections, Intravenous; D054709:Lecithins / Q000737:chemistry; D008055:Lipids / Q000737:chemistry*; D046529:Microscopy, Electron, Transmission; D050178:Monoglycerides; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D020442:Poloxamer / Q000737:chemistry; D051381:Rats; D012997:Solvents; D013228:Stearates / Q000737:chemistry; D014018:Tissue Distribution
chemical_list: D000890:Anti-Infective Agents; D004655:Emulsions; D005079:Excipients; D006027:Glycosides; D054709:Lecithins; D008055:Lipids; D050178:Monoglycerides; D012997:Solvents; D013228:Stearates; C480659:polyglycerol monostearate; D020442:Poloxamer; C038066:syringopicroside; D005990:Glycerol